C:\Documents and Settings\EBernhardt\My Documents\Stnexp\Queries\10763241.str

Part I





chain nodes :
7 8 9 10 11 12 24 25
ring nodes :
1 2 3 4 5 6 13 14 15 16 17 18 19 20 21
chain bonds :
2-11 5-7 7-8 8-9 8-10 10-24 11-12 12-20 24-25
ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6 13-14 13-18 14-15 15-16 16-17 17-18
17-19 18-21 19-20 20-21
exact/norm bonds :
1-2 1-6 2-3 2-11 3-4 4-5 5-6 5-7 8-9 8-10 11-12 12-20 17-19
18-21 19-20 20-21
exact bonds :
7-8 10-24 24-25
normalized bonds :
13-14 13-18 14-15 15-16 16-17 17-18

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:CLASS 8:CLASS 9:CLASS
10:CLASS 11:CLASS 12:CLASS 13:Atom 14:Atom 15:Atom 16:Atom 17:Atom
18:Atom 19:Atom 20:Atom 21:Atom 24:Atom 25:CLASS
Generic attributes :
24:
Saturation : Unsaturated
Number of Carbon Atoms : less than 7
Type of Ring System : Monocyclic

=>
Uploading C:\Documents and Settings\EBernhardt\My Documents\Stnexp\Queries\10763241.str



chain nodes :
7 8 9 10 11 12 24 25
ring nodes :
1 2 3 4 5 6 13 14 15 16 17 18 19 20 21
chain bonds :
2-11 5-7 7-8 8-9 8-10 10-24 11-12 12-20 24-25
ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6 13-14 13-18 14-15 15-16 16-17 17-18 17-19 18-21 19-20 20-21
exact/norm bonds :
1-2 1-6 2-3 2-11 3-4 4-5 5-6 5-7 8-9 8-10 11-12 12-20 17-19 18-21 19-20 20-21
exact bonds :
7-8 10-24 24-25
normalized bonds :
13-14 13-18 14-15 15-16 16-17 17-18

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:CLASS 8:CLASS 9:CLASS 10:CLASS 11:CLASS 12:CLASS 13:Atom 14:Atom 15:Atom 16:Atom 17:Atom 18:Atom 19:Atom 20:Atom 21:Atom 24:Atom 25:CLASS
Generic attributes :
24:
Saturation : Unsaturated
Number of Carbon Atoms : less than 7
Type of Ring System : Monocyclic

L1 STRUCTURE UPLOADED

=> s l1
SAMPLE SEARCH INITIATED 18:45:21 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 5 TO ITERATE

100.0% PROCESSED 5 ITERATIONS 0 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 5 TO 234
PROJECTED ANSWERS: 0 TO 0

L2 0 SEA SSS SAM L1

=> s l1 sss full
FULL SEARCH INITIATED 18:45:54 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 128 TO ITERATE

100.0% PROCESSED 128 ITERATIONS 7 ANSWERS
SEARCH TIME: 00.00.01

L3 7 SEA SSS FUL L1

=> file caplus
COST IN U.S. DOLLARS SINCE FILE ENTRY TOTAL SESSION
FULL ESTIMATED COST 168.70 168.91

FILE 'CAPLUS' ENTERED AT 18:45:59 ON 02 FEB 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

FILE COVERS 1907 - 2 Feb 2006 VOL 144 ISS 6
FILE LAST UPDATED: 1 Feb 2006 (20060201/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply.
They are available for your review at:

http://www.cas.org/infopolicy.html

=> s l3
L4 4 L3

=> d l4 1-3 bib abs hitstr

L4 ANSWER 1 OF 4 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2005:672882 CAPLUS
DN 143:172898
TI A preparation of [(benzoxazolylthio)ethyl]piperazine derivative, useful as acyl coenzyme A cholesterol acyltransferase (ACAT) inhibitor
IN Shibuya, Kimiyuki; Miura, Toru
PA Kowa Co., Ltd., Japan
SO U.S. Pat. Appl. Publ., 10 pp.
CODEN: USXXCO
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2005165026	A1	20050728	US 2004-763241	20040126
	WO 2005070907	A1	20050804	WO 2005-JP1297	20050125

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI,

NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY,
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM,
AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT,
RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML,
MR, NE, SN, TD, TG
PRAI US 2004-763241 A 20040126
GI



I



II



III

AB The invention relates to a prepn. of [(benzoxazolylthio)ethyl]piperazine deriv. (I), useful as acyl CoA cholesterol acyltransferase (ACAT) inhibitor. The above-described compd. has both an inhibitory action on ACAT in the artery wall and remarkably high metabolic resistance in human liver microsomes, and exhibits excellent effects for suppressing lipids depression in aorta. The invention compd. is useful as a highly effective preventive or remedy for hyperlipidemia and arteriosclerosis with less side effects. Compd. I was prepd. via amination of bromoacetamide deriv. II with di-trifluoroacetate of piperazine deriv. III and subsequent hydrolysis (yields: amination - 91.1%, hydrolysis - 86.6%).

IT **500735-37-5P**
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of [(benzoxazolylthio)ethyl]piperazine deriv. useful as acyl CoA cholesterol acyltransferase (ACAT) inhibitor)

RN 500735-37-5 CAPLUS

CN 1-Piperazineacetamide, N-[4-hydroxy-2,6-bis(1-methylethyl)phenyl]-4-[2-[[7-(trifluoromethyl)-2-benzoxazolyl]thio]ethyl]- (9CI) (CA INDEX NAME)



L4 ANSWER 2 OF 4 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2004:162460 CAPLUS
DN 140:217669
TI Preparation of novel cyclic diamine compounds as inhibitors of acyl CoA cholesterol acyltransferase (ACAT)
IN Shibuya, Kimiyuki; Kawamine, Katsumi; Sato, Yukihiro; Miura, Toru; Ozaki, Chiyoka; Edano, Toshiyuki; Hirata, Mitsuteru; Ohgiya, Tadaaki
PA Kowa Company, Ltd., Japan
SO U.S. Pat. Appl. Publ., 95 pp., Cont.-in-part of U.S. Ser. No. 424,417, abandoned.
CODEN: USXXCO
DT Patent
LA English
FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2004038987	A1	20040226	US 2003-371234	20030220
	US 6969711	B2	20051129		
	WO 9854153	A1	19981203	WO 1998-JP2300	19980526

W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG

PRAI	JP 1997-149892	A	19970526
	WO 1998-JP2300	A	19980526
	US 2000-424417	B2	20000330

OS MARPAT 140:217669
GI



I



II

AB The title substituted piperazines and homopiperazines (1,4-diazepines) I [ring A = (un)substituted benzene, pyridine, cyclohexane, or naphthalene or vinylene divalent residue; Ar = (un)substituted aryl; X = NH, O, S; Y = NR1, O, S, SO, SO2; Z = single bond or NR2; R1, R2 = H, (un)substituted alkyl, aryl, silylalkyl; l = 0-15; m = 2-3; n = 0-3] and salts or solvates, useful for therapy or prevention of hyperlipidemia, arteriosclerosis, cerebrovascular disorder, ischemic cardiopathy, ischemic entheropathy or aortic aneurysm, were prepd. Thus, N-(2,6-diisopropylphenyl)-2-[4-(2-hydroxyethyl)piperazin-1-yl]acetamide was mesylated in the presence of Et3N and 4-dimethylaminopyridine in THF and then condensed with 2-mercaptobenzoxazole to give the title compd. [II; X = O]. The latter compd. and II [X = NH] showed IC50 of 0.024 and 0.011 .mu.M against ACAT derived from rabbit blood cell wall, resp., and 0.045 and 0.051 against ACAT derived from rabbit small intestine, resp. The pharmaceutical compn. comprising the compd. I is claimed.

IT **500735-37-5P**
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(prepn. of substituted (homo)piperazines as inhibitors of acyl CoA cholesterol acyltransferase (ACAT))

RN 500735-37-5 CAPLUS

CN 1-Piperazineacetamide, N-[4-hydroxy-2,6-bis(1-methylethyl)phenyl]-4-[2-[[7-(trifluoromethyl)-2-benzoxazolyl]thio]ethyl]- (9CI) (CA INDEX NAME)



IT **217094-88-7P 217094-93-4P 217094-99-0P**
500735-38-6P 664340-14-1P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of substituted (homo)piperazines as inhibitors of acyl CoA cholesterol acyltransferase (ACAT))

RN 217094-88-7 CAPLUS

CN 1-Piperazineacetamide, 4-[2-(2-benzoxazolylthio)ethyl]-N-[3-hydroxy-2,6-bis(1-methylethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 217094-93-4 CAPLUS
CN 1-Piperazineacetamide, 4-[2-(2-benzoxazolylthio)ethyl]-N-[3-hydroxy-2,6-bis(1-methylethyl)-4-nitrophenyl]- (9CI) (CA INDEX NAME)



RN 217094-99-0 CAPLUS
CN 1-Piperazineacetamide, 4-[2-(2-benzoxazolylthio)ethyl]-N-[4-hydroxy-2,6-bis(1-methylethyl)phenyl]- (9CI) (CA INDEX NAME)



RN 500735-38-6 CAPLUS
CN 1-Piperazineacetamide, N-[3-hydroxy-2,6-bis(1-methylethyl)phenyl]-4-[2-[[7-(trifluoromethyl)-2-benzoxazolyl]thio]ethyl]- (9CI) (CA INDEX NAME)



RN 664340-14-1 CAPLUS
CN 1-Piperazineacetamide, 4-[2-[[5-chloro-4-methyl-7-(1-methylethyl)-2-benzoxazolyl]thio]ethyl]-N-[4-hydroxy-2,6-bis(1-methylethyl)phenyl]- (9CI) (CA INDEX NAME)



RE.CNT 14 THERE ARE 14 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 3 OF 4 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2003:173590 CAPLUS
DN 138:221603
TI Preparation of 2-[4-[2-(7-trifluoromethylbenzoxazol-2-ylthio)ethyl]piperadin-1-yl]-N-(2,6-diisopropyl-4-hydroxyphenyl)acetamide as vascular wall-selective ACAT inhibitor for treatment of hyperlipidemia and arteriosclerosis
IN Shibuya, Kimiyuki; Kawamine, Katsumi; Oogiya, Tadaaki; Kitamura, Takahiro; Miura, Toru; Edano, Toshiyuki; Yoshinaka, Yasunobu; Yamada, Youichi
PA Kowa Co., Ltd., Japan
SO PCT Int. Appl., 42 pp.
CODEN: PIXXD2
DT Patent
LA Japanese
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003018564	A1	20030306	WO 2002-JP8343	20020819
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	EP 1431294	A1	20040623	EP 2002-760658	20020819
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK				
PRAI	JP 2001-251099	A	20010822		
	WO 2002-JP8343	W	20020819		

OS MARPAT 138:221603
GI



I



II

AB The title compds. I [wherein A = (un)substituted Ph, Py, cyclohexyl, naphthyl, or none; Ar = (un)substituted aryl; X = NH, O, or S; Y = O, S, SO, SO2, or (un)substituted imino; Z = a single bond or (un)substituted imino; p = 0-15; m = 2-3; n = 0-3] and salts or solvates thereof are prepd. as acyl CoA cholesterol acyltransferase (ACAT) inhibitors, which have good macrophage selectivity, for the treatment of hyperlipidemia and arteriosclerosis. For example, the compd. II.bul.HCl was prepd. in a 4-step synthesis comprising a coupling reaction in good yield. II.bul.HCl showed IC50 of 65 and 2900 nM in vitro against J774 and HepG2 cell, resp., with a macrophage selectivity of 45.

IT **500735-37-5P**

RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)

(ACAT inhibitor; prepn. of [[(benzoxazolylthio)ethyl]piperidinylacetamide as vascular wall-selective ACAT inhibitor for treatment of hyperlipidemia and arteriosclerosis)

RN 500735-37-5 CAPLUS

CN 1-Piperazineacetamide, N-[4-hydroxy-2,6-bis(1-methylethyl)phenyl]-4-[2-[[7-(trifluoromethyl)-2-benzoxazolyl]thio]ethyl]- (9CI) (CA INDEX NAME)



IT **500735-36-4P 500735-38-6P**

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(ACAT inhibitor; prepn. of [[(benzoxazolylthio)ethyl]piperidinylacetamide as vascular wall-selective ACAT inhibitor for treatment of hyperlipidemia and arteriosclerosis)

RN 500735-36-4 CAPLUS
CN 1-Piperazineacetamide, N-[4-hydroxy-2,6-bis(1-methylethyl)phenyl]-4-[2-[[7-(trifluoromethyl)-2-benzoxazolyl]thio]ethyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 500735-38-6 CAPLUS
CN 1-Piperazineacetamide, N-[3-hydroxy-2,6-bis(1-methylethyl)phenyl]-4-[2-[[7-(trifluoromethyl)-2-benzoxazolyl]thio]ethyl]- (9CI) (CA INDEX NAME)



IT **217094-99-0**
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(ACAT inhibitor; prepn. of [[(benzoxazolylthio)ethyl]piperidinylacetamide as vascular wall-selective ACAT inhibitor for treatment of hyperlipidemia and arteriosclerosis)
RN 217094-99-0 CAPLUS
CN 1-Piperazineacetamide, 4-[2-(2-benzoxazolylthio)ethyl]-N-[4-hydroxy-2,6-bis(1-methylethyl)phenyl]- (9CI) (CA INDEX NAME)



RE.CNT 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> file caold
COST IN U.S. DOLLARS SINCE FILE TOTAL

	ENTRY	SESSION
FULL ESTIMATED COST	15.79	184.70

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-2.25	-2.25

FILE 'CAOLD' ENTERED AT 18:46:26 ON 02 FEB 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

FILE COVERS 1907-1966
FILE LAST UPDATED: 01 May 1997 (19970501/UP)

This file contains CAS Registry Numbers for easy and accurate substance identification. Title keywords, authors, patent assignees, and patent information, e.g., patent numbers, are now searchable from 1907-1966. TIFF images of CA abstracts printed between 1907-1966 are available in the PAGE display formats.

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file supports REG1stRY for direct browsing and searching of all substance data from the REGISTRY file. Enter HELP FIRST for more information.

=> s l3
L5 0 L3

=> log h

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.44	185.14

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	0.00	-2.25

SESSION WILL BE HELD FOR 60 MINUTES
STN INTERNATIONAL SESSION SUSPENDED AT 18:46:37 ON 02 FEB 2006